MX2010009403A - Derivados de 2-aminoquinolina. - Google Patents
Derivados de 2-aminoquinolina.Info
- Publication number
- MX2010009403A MX2010009403A MX2010009403A MX2010009403A MX2010009403A MX 2010009403 A MX2010009403 A MX 2010009403A MX 2010009403 A MX2010009403 A MX 2010009403A MX 2010009403 A MX2010009403 A MX 2010009403A MX 2010009403 A MX2010009403 A MX 2010009403A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- present
- concerned
- aminoquinoline derivatives
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención se refiere a los derivados de 2-aminoquinolina como antagonistas del receptor 5-HT5A, su elaboración, composiciones farmacéuticas que los contienen y su uso como medicamentos. Los compuestos activos de la presente invención son útiles en la prevención y/o tratamiento de la depresión, trastornos de ansiedad, esquizofrenia, trastornos de pánico, agorafobia, fobia social, trastornos obsesivos compulsivos, trastornos post-traumáticos de estrés, dolor, trastornos de memoria, demencia, trastornos de comportamientos de alimentación, disfunción sexual, trastornos de sueño, abuso de drogas, trastornos motores tales como enfermedad de Parkinson, trastornos psiquiátricos o trastornos gastrointestinales. En particular, la presente invención se refiere a los compuestos de la fórmula general (I), en donde R1 y R2 son como se describió aquí.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08152421 | 2008-03-07 | ||
PCT/EP2009/052193 WO2009109491A1 (en) | 2008-03-07 | 2009-02-25 | 2-aminoquinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009403A true MX2010009403A (es) | 2010-09-24 |
Family
ID=40577705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009403A MX2010009403A (es) | 2008-03-07 | 2009-02-25 | Derivados de 2-aminoquinolina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US7994324B2 (es) |
EP (1) | EP2262773A1 (es) |
JP (1) | JP2011514898A (es) |
KR (1) | KR20100109978A (es) |
CN (1) | CN101959864A (es) |
AU (1) | AU2009221389A1 (es) |
BR (1) | BRPI0910253A2 (es) |
CA (1) | CA2715842A1 (es) |
IL (1) | IL206949A0 (es) |
MX (1) | MX2010009403A (es) |
WO (1) | WO2009109491A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010009574A (es) * | 2008-03-05 | 2010-09-24 | Hoffmann La Roche | 2-aminoquinolinas. |
KR20100120716A (ko) * | 2008-03-07 | 2010-11-16 | 에프. 호프만-라 로슈 아게 | 5-ht(5a) 수용체 길항제로서의 2-아미노퀴놀린 유도체 |
AU2014334554B2 (en) | 2013-10-14 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
MX363708B (es) | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176454A1 (en) | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
SE0103649D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
WO2004034985A2 (en) * | 2002-10-16 | 2004-04-29 | Smithkline Beecham Corporation | Chemical compounds |
WO2004080463A1 (en) * | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
NZ560917A (en) | 2005-03-31 | 2011-01-28 | Pfizer Prod Inc | Cyclopentapyridine and tetrahydroquinoline derivatives |
TWI291826B (en) * | 2006-02-27 | 2007-12-21 | Inventec Appliances Corp | Method for activating different functions of hot key at different time and the device thereof |
ATE478050T1 (de) | 2006-09-28 | 2010-09-15 | Hoffmann La Roche | Chinolinderivate mit 5-ht-bindenden eigenschaften |
CA2669590A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | 2-aminoquinolines as 5-ht(5a) receptor antagonists |
KR20100120716A (ko) * | 2008-03-07 | 2010-11-16 | 에프. 호프만-라 로슈 아게 | 5-ht(5a) 수용체 길항제로서의 2-아미노퀴놀린 유도체 |
-
2009
- 2009-02-25 MX MX2010009403A patent/MX2010009403A/es active IP Right Grant
- 2009-02-25 JP JP2010549094A patent/JP2011514898A/ja active Pending
- 2009-02-25 CA CA2715842A patent/CA2715842A1/en not_active Abandoned
- 2009-02-25 BR BRPI0910253A patent/BRPI0910253A2/pt not_active IP Right Cessation
- 2009-02-25 AU AU2009221389A patent/AU2009221389A1/en not_active Abandoned
- 2009-02-25 CN CN2009801062820A patent/CN101959864A/zh active Pending
- 2009-02-25 EP EP09717300A patent/EP2262773A1/en not_active Withdrawn
- 2009-02-25 KR KR1020107019840A patent/KR20100109978A/ko active IP Right Grant
- 2009-02-25 WO PCT/EP2009/052193 patent/WO2009109491A1/en active Application Filing
- 2009-02-27 US US12/394,092 patent/US7994324B2/en not_active Expired - Fee Related
-
2010
- 2010-07-12 IL IL206949A patent/IL206949A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009109491A1 (en) | 2009-09-11 |
EP2262773A1 (en) | 2010-12-22 |
IL206949A0 (en) | 2010-12-30 |
KR20100109978A (ko) | 2010-10-11 |
US20090227584A1 (en) | 2009-09-10 |
CA2715842A1 (en) | 2009-09-11 |
JP2011514898A (ja) | 2011-05-12 |
US7994324B2 (en) | 2011-08-09 |
CN101959864A (zh) | 2011-01-26 |
AU2009221389A1 (en) | 2009-09-11 |
BRPI0910253A2 (pt) | 2015-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
WO2008080844A9 (en) | Azaspiro derivatives | |
WO2006119504A3 (en) | Fused heterocyclic compounds, and compositions and uses thereof | |
WO2007076875A3 (en) | Compounds acting on the serotonin transporter | |
WO2008050341A3 (en) | Novel psychotropic agents having glutamate nmda activity | |
MX2009005507A (es) | Derivados de espiro-piperidina. | |
CY1110531T1 (el) | 6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c | |
NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
JP2007523206A5 (es) | ||
DE602007004881D1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
WO2008077810A3 (en) | Spiro-piperidine derivatives | |
ATE502026T1 (de) | Verbindungen mit kombinierten cannabinoid-cb1- antagonismus und acetylcholinesterasehemmung | |
WO2010026110A3 (en) | 6-substituted benzoxazines as 5-ht-5a receptor antagonists | |
MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
MX2009005544A (es) | Indoles. | |
MX2010008239A (es) | 2-aminoquinolinas. | |
MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
IL188115A0 (en) | 8-alkoxy-4-methyl-3,4-dihdro-quinazolin-2- | |
TW200833696A (en) | Spiro-piperidine derivatives | |
IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin | |
ATE440826T1 (de) | Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen | |
ATE505193T1 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |